HALO
Halozyme Therapeutics Inc
109.80$
-0.9%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 100.0% | 100.0% | 100.0% | 98.4% | 98.0% | 98.9% | 97.8% | 96.7% | 96.5% | 98.0% | 97.3% | 97.3% | 93.5% | 97.2% | 94.5% | 98.1% | 98.2% | 97.2% | 96.0% | 95.7% | 83.9% | 40.1% | 43.1% | 52.6% | 32.7% | |
| 100.0% | 100.0% | 100.0% | 97.6% | 93.3% | 95.9% | 94.4% | 83.2% | 87.4% | 91.1% | 80.3% | 74.2% | 26.9% | 37.0% | 23.8% | 25.5% | 32.5% | 13.2% | 21.2% | 25.5% | 10.7% | 12.7% | 6.8% | 5.6% | 5.3% | |
| 100.0% | 100.0% | 100.0% | 97.6% | 93.3% | 95.9% | 94.4% | 83.2% | 87.4% | 91.1% | 80.3% | 74.2% | 70.2% | 81.7% | 59.6% | 78.4% | 90.2% | 80.5% | 74.4% | 63.5% | 67.1% | 19.7% | 19.4% | 28.9% | 5.7% | |
| – | – | – | – | 2.0% | 1.2% | 0.8% | 9.5% | 5.5% | 2.5% | 3.4% | 11.7% | 8.9% | 5.5% | 17.8% | 6.0% | 4.3% | 6.8% | 10.5% | 16.9% | 8.2% | 12.5% | 13.5% | 14.9% | 17.5% | |
| – | – | – | 0.3% | 1.4% | 1.0% | 0.7% | 0.6% | 1.5% | 0.2% | 0.9% | 2.0% | 6.1% | 3.9% | 5.2% | 5.6% | 1.0% | 5.1% | 5.2% | 10.5% | 4.9% | 5.4% | 7.4% | 6.9% | 7.0% | |
| – | – | – | 1.4% | 1.9% | 1.1% | 2.2% | 3.3% | 3.5% | 2.0% | 2.7% | 2.7% | 3.4% | 1.8% | 2.2% | 1.6% | 0.7% | 1.7% | 1.9% | 1.8% | 0.8% | 4.1% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | 0.0% | 22.2% | 24.0% | 20.2% | 23.0% | |
| – | – | – | – | – | – | – | – | – | – | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | 29.7% | 27.3% | 19.5% | 38.9% | |
| 12.6% | 10.7% | 78.8% | 9.6% | 11.2% | 49.9% | 44.2% | 79.9% | 91.1% | 77.7% | 83.4% | 63.7% | 119.6% | 75.1% | 76.3% | 112.4% | 59.9% | 43.5% | 83.8% | 74.0% | 82.2% | 90.8% | 95.2% | 82.4% | 98.1% | |
| 12.6% | 10.7% | 78.8% | 9.6% | 11.2% | 9.2% | 8.6% | 18.6% | 18.7% | 16.8% | 26.3% | 14.1% | 25.0% | 14.7% | 34.4% | 20.9% | 25.3% | 33.9% | 15.1% | 72.7% | 10.6% | 7.1% | 6.5% | 6.7% | 7.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | 30.0% | 12.0% | 6.7% | 14.8% | 20.8% | 3.5% | 68.5% | 8.1% | 0.7% | 0.4% | – | – | |
| – | – | 68.8% | 9.1% | 6.7% | 4.4% | 3.0% | 8.7% | 3.7% | 4.2% | 11.5% | 1.7% | 3.1% | 1.8% | 2.5% | 1.4% | 1.5% | 0.9% | 1.1% | 0.3% | 0.1% | 1.0% | 0.7% | 0.5% | 0.8% | |
| – | – | – | – | – | – | – | – | – | – | 0.0% | 22.0% | 48.9% | 30.0% | 15.4% | 76.2% | 24.1% | 7.9% | 67.7% | – | 71.3% | 81.1% | 86.5% | 73.0% | 84.8% | |
| 87.4% | 89.3% | 21.2% | 90.4% | 88.8% | 50.1% | 55.8% | 20.1% | 8.9% | 22.3% | 16.6% | 36.3% | -19.6% | 24.9% | 23.7% | -12.4% | 40.1% | 56.5% | 16.2% | 26.0% | 17.8% | 9.2% | 4.8% | 17.6% | 1.9% | |
| -151.8% | -107.9% | -387.2% | -79.7% | -128.5% | -89.2% | -62.8% | -148.4% | -223.0% | -246.6% | -372.6% | -221.6% | -375.3% | -271.4% | -265.5% | -223.8% | -100.5% | -120.7% | -106.7% | -81.8% | -5.3% | 7.8% | 5.2% | 17.4% | 2.2% | |
| 4,590.8% | 4,729.7% | 14,365.6% | 215.9% | 245.3% | 135.8% | 71.8% | 104.3% | 112.4% | 103.3% | 156.0% | 82.4% | 110.8% | 73.9% | 69.7% | 48.9% | 26.7% | 32.6% | 25.5% | 24.4% | 13.3% | 7.6% | 7.7% | 6.3% | 4.9% |
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.